Cour RPC Sein 2016 - page 99

Buyse M, Wong A, Bryce R, Ye Y, Martin M. Neratinib after trastuzumab-based
adjuvant therapy in early-stage HER2+ breast cancer: 3-year analysis from a phase 3
randomized, placebo-controlled, double-blind trial (ExteNET). SABCS 2015, S5-02.
13.Vaz-Luis I,Ottesen RA,Hughes ME,Mamet R,Burstein HJ,Edge SB,Gonzalez-
Angulo AM, Moy B, Rugo HS, Theriault RL, Weeks JC, Winer EP, Lin NU.
Outcomes by tumor subtype and treatment pattern in women with small, node-
negative breast cancer: a multi-institutional study.J Clin Oncol.2014 Jul
10;32(20):2142-50.
14.Fehrenbacher L, Capra AM, Quesenberry CP Jr, Fulton R, Shiraz P, Habel LA.
Distant invasive breast cancer recurrence risk in human epidermal growth factor
receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from
2000 to 2006: a cohort from an integrated health care delivery system. J Clin Oncol.
2014 Jul 10;32(20):2151-8.
15. Van Ramshorst MS, Van der Heijden-van der Loo M, Dackus GMHE, Linn SC,
Sonke GS. The effect of trastuzumab_based therapy on overall survival in small, node-
negative HER2-positive breast cancer: To treat or not to treat ? SABCS 2015, S6-06.
16. NCCN Clinical guidelines in Oncology. Breast Cancer. Version 3.2014.
6